GIVN From the 'Globes' piece:The company hopes to obtain US Food and Drug Administration (FDA) approval by the end of the year. US marketing approval and insurance indemnification will add another $1.7 billion market.They didn't mention that if approved (and chances seem good), it will be for a fairly narrow indication.